Skip to main navigation
Skip to search
Skip to main content
Technical University of Munich Home
Help & FAQ
English
Deutsch
Home
Profiles
Research units
Projects
Research output
Datasets
Prizes
Activities
Press/Media
Impacts
Search by expertise, name or affiliation
HDAC expression and clinical prognosis in human malignancies
Wilko Weichert
Charité – Universitätsmedizin Berlin
Research output
:
Contribution to journal
›
Review article
›
peer-review
358
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'HDAC expression and clinical prognosis in human malignancies'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Clinical Prognosis
100%
Human Malignancies
100%
Histone Deacetylase 1 (HDAC1)
100%
Tumor
25%
Expression Pattern
25%
Human Tumors
25%
Histone Deacetylase Inhibitor (HDACi)
25%
Biological Role
12%
Protein Level
12%
MRNA Level
12%
Patient Outcomes
12%
Hematological Malignancies
12%
Histone Deacetylases
12%
Translational Studies
12%
High-level Expression
12%
Response to Treatment
12%
Solid Malignancies
12%
Neoplasia
12%
Patient Prognosis
12%
Locally Advanced
12%
Cell Properties
12%
Tumor Expression
12%
Enhanced Expression
12%
Tissue of Origin
12%
Anticancer Agents
12%
Dedifferentiated
12%
Isoform Expression
12%
Improved Prognosis
12%
Class II HDAC
12%
Medicine and Dentistry
Cancer
100%
Histone Deacetylase
100%
Neoplasm
66%
Histone Deacetylase Inhibitor
22%
Malignant Neoplasm
11%
Hematologic Malignancy
11%
Messenger RNA
11%
Anticancer Drug
11%
Pharmacology, Toxicology and Pharmaceutical Science
Histone Deacetylase
100%
Neoplasm
66%
Histone Deacetylase Inhibitor
22%
Malignant Neoplasm
11%
Hematologic Malignancy
11%
Messenger RNA
11%
Anticancer Drug
11%
Biochemistry, Genetics and Molecular Biology
Histone Deacetylase
100%
Isoform
36%
Anticancer
9%
Messenger RNA
9%